AR040367A1 - Anticuerpos humanizados contra el receptor de linfotoxina beta - Google Patents
Anticuerpos humanizados contra el receptor de linfotoxina betaInfo
- Publication number
- AR040367A1 AR040367A1 ARP030102391A ARP030102391A AR040367A1 AR 040367 A1 AR040367 A1 AR 040367A1 AR P030102391 A ARP030102391 A AR P030102391A AR P030102391 A ARP030102391 A AR P030102391A AR 040367 A1 AR040367 A1 AR 040367A1
- Authority
- AR
- Argentina
- Prior art keywords
- cancer
- antibodies
- beta
- seq
- amino acid
- Prior art date
Links
- 206010009944 Colon cancer Diseases 0.000 abstract 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 2
- 208000005718 Stomach Neoplasms Diseases 0.000 abstract 2
- 125000000539 amino acid group Chemical group 0.000 abstract 2
- 206010017758 gastric cancer Diseases 0.000 abstract 2
- 208000002154 non-small cell lung carcinoma Diseases 0.000 abstract 2
- 102000005962 receptors Human genes 0.000 abstract 2
- 108020003175 receptors Proteins 0.000 abstract 2
- 201000011549 stomach cancer Diseases 0.000 abstract 2
- 208000029729 tumor suppressor gene on chromosome 11 Diseases 0.000 abstract 2
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 abstract 1
- 206010005003 Bladder cancer Diseases 0.000 abstract 1
- 206010006187 Breast cancer Diseases 0.000 abstract 1
- 208000026310 Breast neoplasm Diseases 0.000 abstract 1
- 208000000461 Esophageal Neoplasms Diseases 0.000 abstract 1
- 102000004083 Lymphotoxin-alpha Human genes 0.000 abstract 1
- 108090000542 Lymphotoxin-alpha Proteins 0.000 abstract 1
- 206010030155 Oesophageal carcinoma Diseases 0.000 abstract 1
- 206010060862 Prostate cancer Diseases 0.000 abstract 1
- 208000000236 Prostatic Neoplasms Diseases 0.000 abstract 1
- 208000000453 Skin Neoplasms Diseases 0.000 abstract 1
- 208000007097 Urinary Bladder Neoplasms Diseases 0.000 abstract 1
- 239000002246 antineoplastic agent Substances 0.000 abstract 1
- 229940127089 cytotoxic agent Drugs 0.000 abstract 1
- 238000002405 diagnostic procedure Methods 0.000 abstract 1
- 201000004101 esophageal cancer Diseases 0.000 abstract 1
- 230000000984 immunochemical effect Effects 0.000 abstract 1
- 201000000849 skin cancer Diseases 0.000 abstract 1
- 238000002560 therapeutic procedure Methods 0.000 abstract 1
- 201000005112 urinary bladder cancer Diseases 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39299302P | 2002-07-01 | 2002-07-01 | |
| US41737202P | 2002-10-09 | 2002-10-09 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR040367A1 true AR040367A1 (es) | 2005-03-30 |
Family
ID=30003289
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP030102391A AR040367A1 (es) | 2002-07-01 | 2003-07-01 | Anticuerpos humanizados contra el receptor de linfotoxina beta |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7429645B2 (enExample) |
| EP (1) | EP1539793A4 (enExample) |
| JP (1) | JP2005532051A (enExample) |
| CN (1) | CN1678625A (enExample) |
| AR (1) | AR040367A1 (enExample) |
| AU (1) | AU2003248782A1 (enExample) |
| CA (1) | CA2491480A1 (enExample) |
| NZ (1) | NZ537965A (enExample) |
| TW (1) | TW200416044A (enExample) |
| WO (1) | WO2004002431A2 (enExample) |
Families Citing this family (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6312691B1 (en) * | 1996-01-26 | 2001-11-06 | Jeffrey L. Browning | Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents |
| US5925351A (en) | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
| SG121778A1 (en) * | 1998-10-09 | 2006-05-26 | Univ Emory | Reversal of viral-induced systemic shock and respiratory distress by blockade of the lymphotoxin beta pathway |
| SK5672003A3 (en) * | 2000-10-13 | 2003-10-07 | Biogen Inc | Humanized anti-LT-beta-R antibodies |
| PL377611A1 (pl) * | 2002-12-20 | 2006-02-06 | Biogen Idec Ma Inc. | Czynniki dla receptora limfotoksyny beta w połączeniu z czynnikami chemioterapeutycznymi |
| CN100473664C (zh) * | 2002-12-20 | 2009-04-01 | 拜奥根Idec马萨诸塞公司 | 多价淋巴毒素β受体激动剂及其治疗用途 |
| CA2529945A1 (en) * | 2003-06-27 | 2005-01-06 | Biogen Idec Ma Inc. | Use of hydrophobic-interaction-chromatography or hinge-region modifications for the production of homogeneous antibody-solutions |
| JP2005241389A (ja) * | 2004-02-25 | 2005-09-08 | Ochiyanomizu Jiyoshi Univ | 蛍光標識糖鎖の特異的固定化試薬および固定化方法 |
| WO2005092927A1 (en) | 2004-03-23 | 2005-10-06 | Biogen Idec Ma Inc. | Receptor coupling agents and therapeutic uses thereof |
| WO2006074399A2 (en) * | 2005-01-05 | 2006-07-13 | Biogen Idec Ma Inc. | Multispecific binding molecules comprising connecting peptides |
| EP2067041A2 (en) | 2006-10-03 | 2009-06-10 | Biogen Idec MA, Inc. | Biomarkers and assays for the treatment of cancer |
| PE20080980A1 (es) | 2006-10-12 | 2008-09-02 | Genentech Inc | Anticuerpos anti-linfotoxina alfa |
| CA2666934A1 (en) * | 2006-10-20 | 2008-04-24 | Biogen Idec Ma Inc. | Treatment of demyelinating disorders with soluble lymphotoxin-beta-receptor |
| US8338376B2 (en) * | 2006-10-20 | 2012-12-25 | Biogen Idec Ma Inc. | Compositions comprising variant LT-B-R-IG fusion proteins |
| PL2158315T3 (pl) | 2007-06-25 | 2016-10-31 | Sposoby modyfikowania przeciwciał i zmodyfikowane przeciwciała o ulepszonych właściwościach funkcjonalnych | |
| AU2009334498A1 (en) * | 2008-12-31 | 2011-07-21 | Biogen Idec Ma Inc. | Anti-lymphotoxin antibodies |
| RU2012153241A (ru) * | 2010-05-11 | 2014-06-20 | Авео Фармасьютикалз, Инк. | Антитела к fgfr2 |
| TWI897855B (zh) * | 2018-10-26 | 2025-09-21 | 美商免疫遺傳股份有限公司 | Ｅ ｐ Ｃ Ａ Ｍ 抗體、可活化抗體及免疫偶聯物以及其用途 |
| CA3164226A1 (en) | 2019-12-11 | 2021-06-17 | Cilag Gmbh International | Multispecific binding molecules comprising ltbr and edb binding domains and uses thereof |
| US11883432B2 (en) | 2020-12-18 | 2024-01-30 | Century Therapeutics, Inc. | Chimeric antigen receptor system with adaptable receptor specificity |
| CR20240246A (es) * | 2021-12-20 | 2024-07-19 | Hoffmann La Roche | Anticuerpos agonistas anti-ltbr y anticuerpos biespecificos que los comprenden |
| WO2023218320A1 (en) * | 2022-05-11 | 2023-11-16 | Pfizer Inc. | Anti-lymphotoxin beta receptor antibodies and methods of use thereof |
| WO2025012620A1 (en) | 2023-07-07 | 2025-01-16 | Mestag Therapeutics Ltd | Binding constructs |
| EP4527851A1 (en) | 2023-09-22 | 2025-03-26 | Bayer Aktiengesellschaft | Bispecific antibodies binding ltbr and lrrc15 |
| WO2025172588A1 (en) | 2024-02-16 | 2025-08-21 | Mestag Therapeutics Ltd | Bispecific constructs directed against fap and ltbr |
| WO2025172587A1 (en) | 2024-02-16 | 2025-08-21 | Mestag Therapeutics Ltd | Binding constructs |
| WO2025221728A2 (en) | 2024-04-15 | 2025-10-23 | Janssen Biotech, Inc. | Ltbr binding molecules and uses thereof |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5618920A (en) * | 1985-11-01 | 1997-04-08 | Xoma Corporation | Modular assembly of antibody genes, antibodies prepared thereby and use |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| US5859205A (en) * | 1989-12-21 | 1999-01-12 | Celltech Limited | Humanised antibodies |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69132629T2 (de) | 1990-06-27 | 2002-04-18 | Biogen, Inc. | Oberflächenkomplexbildung von lymphotoxin |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| WO1994004679A1 (en) | 1991-06-14 | 1994-03-03 | Genentech, Inc. | Method for making humanized antibodies |
| DE69334224D1 (de) | 1992-12-04 | 2008-07-17 | Biogen Idec Inc | Lymphotoxin-beta, lymphotoxin-beta komplexe, pharmazeutische zubereitungen und therapeutische verwendungen davon |
| DE69632681T2 (de) * | 1995-01-26 | 2005-06-09 | Biogen, Inc., Cambridge | Lymphotoxin-alpha/beta komplexe und antikörper gegen den lymphotoxin-beta rezeptor als agenzien gegen tumoren |
| US6312691B1 (en) * | 1996-01-26 | 2001-11-06 | Jeffrey L. Browning | Lymphotoxin-α/β complexes and anti-lympotoxin-β receptor antibodies as anti-tumor agents |
| US5925351A (en) * | 1995-07-21 | 1999-07-20 | Biogen, Inc. | Soluble lymphotoxin-β receptors and anti-lymphotoxin receptor and ligand antibodies as therapeutic agents for the treatment of immunological disease |
| AU752710B2 (en) | 1998-01-30 | 2002-09-26 | Biogen Idec Ma Inc. | Treatment of follicular lymphomas using inhibitors of the lymphotoxin (LT) pathway |
| US7060667B1 (en) | 1998-01-30 | 2006-06-13 | Biogen Idec Ma, Inc. | Treatment of follicular lymphomas using inhibitors of the LT pathway |
| GB9809839D0 (en) * | 1998-05-09 | 1998-07-08 | Glaxo Group Ltd | Antibody |
| SK5672003A3 (en) | 2000-10-13 | 2003-10-07 | Biogen Inc | Humanized anti-LT-beta-R antibodies |
| PL377611A1 (pl) | 2002-12-20 | 2006-02-06 | Biogen Idec Ma Inc. | Czynniki dla receptora limfotoksyny beta w połączeniu z czynnikami chemioterapeutycznymi |
| CN100473664C (zh) | 2002-12-20 | 2009-04-01 | 拜奥根Idec马萨诸塞公司 | 多价淋巴毒素β受体激动剂及其治疗用途 |
| WO2005092927A1 (en) | 2004-03-23 | 2005-10-06 | Biogen Idec Ma Inc. | Receptor coupling agents and therapeutic uses thereof |
-
2003
- 2003-07-01 NZ NZ537965A patent/NZ537965A/en unknown
- 2003-07-01 CA CA002491480A patent/CA2491480A1/en not_active Abandoned
- 2003-07-01 WO PCT/US2003/020762 patent/WO2004002431A2/en not_active Ceased
- 2003-07-01 CN CNA038207214A patent/CN1678625A/zh active Pending
- 2003-07-01 EP EP03762296A patent/EP1539793A4/en not_active Withdrawn
- 2003-07-01 JP JP2004518186A patent/JP2005532051A/ja active Pending
- 2003-07-01 TW TW092117964A patent/TW200416044A/zh unknown
- 2003-07-01 AR ARP030102391A patent/AR040367A1/es unknown
- 2003-07-01 AU AU2003248782A patent/AU2003248782A1/en not_active Abandoned
-
2004
- 2004-12-23 US US11/021,819 patent/US7429645B2/en not_active Expired - Fee Related
Also Published As
| Publication number | Publication date |
|---|---|
| JP2005532051A (ja) | 2005-10-27 |
| CN1678625A (zh) | 2005-10-05 |
| WO2004002431A2 (en) | 2004-01-08 |
| US7429645B2 (en) | 2008-09-30 |
| CA2491480A1 (en) | 2004-01-08 |
| WO2004002431A3 (en) | 2004-08-26 |
| EP1539793A2 (en) | 2005-06-15 |
| AU2003248782A1 (en) | 2004-01-19 |
| US20060222644A1 (en) | 2006-10-05 |
| EP1539793A4 (en) | 2006-02-01 |
| NZ537965A (en) | 2008-04-30 |
| TW200416044A (en) | 2004-09-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR040367A1 (es) | Anticuerpos humanizados contra el receptor de linfotoxina beta | |
| JP7325463B2 (ja) | がんの予後診断及び治療のための方法及び組成物 | |
| NZ594466A (en) | Human monoclonal antibodies to protein tyrosine kinase 7 (PTK7) and methods for using anti-PTK7 antibodies | |
| RU2008142833A (ru) | КОМПОЗИЦИИ И СПОСОБЫ ПРИМЕНЕНИЯ АНТИТЕЛ К c-Met | |
| RU2014111999A (ru) | Антитела к C10RF32 и их применения для лечения рака | |
| WO2007109376A3 (en) | Anti-tumor cell antigen antibody therapeutics | |
| CN113271942A (zh) | 抗体-药物缀合物与parp抑制剂的组合 | |
| BR112019013238A2 (pt) | Anticorpos anti-pd-1 e usos dos mesmos | |
| BRPI0613382A8 (pt) | anticorpos isolados, anticorpo monoclonal, célula de hibridoma, método de identificação, método de inibição do crescimento de uma célula, método de tratamento terapêutico, método de determinação da presença de uma proteína, métodos de diagnósticos da presença de tumor | |
| CN111278861A (zh) | Pd-l1抗体、其抗原结合片段及医药用途 | |
| JP2009505676A5 (enExample) | ||
| NZ597067A (en) | Monoclonal antibodies expressed by ATCC PTA-4621 for the treatment of cancer | |
| CA2595610A1 (en) | Antibodies directed to angiopoietin-2 and uses thereof | |
| Charlebois et al. | PolyI: C and CpG synergize with anti-ErbB2 mAb for treatment of breast tumors resistant to immune checkpoint inhibitors | |
| RU2014101669A (ru) | Агенты, связывающие белки r-спондины (rspo), и способы их применения | |
| CN101365723A (zh) | 针对her-3的抗体及其用途 | |
| TW201731527A (zh) | 使用抗ｐｄ－１抗體與抗ｃｌｔａ－４抗體之組合以治療肺癌 | |
| US20220396627A1 (en) | Anti-siglec-9 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof | |
| ITMI20031127A1 (it) | Anticorpi anti-hgf-r e loro uso | |
| WO2009019365A3 (fr) | Procede de dosage de l'ezrine pour le diagnostic in vitro du cancer colorectal | |
| JP2008508858A5 (enExample) | ||
| KR20220042055A (ko) | 골수성 세포 염증성 표현형을 조절하기 위한 항-psgl-1 조성물 및 방법, 그리고 이의 용도 | |
| KR20130012132A (ko) | 암의 치료를 위한 인간화 항-cxcr4 항체들 | |
| UY27499A1 (es) | Anticuerpos humanos que se unen a mn y tiene actividad neutralizante de la adhesión celular | |
| KR20220042128A (ko) | 골수성 세포 염증성 표현형을 조절하기 위한 항-cd53 조성물 및 방법, 그리고 이의 용도 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |